Clinical Research Pharmacies and Clinical Trials - Permits and Ownership
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
Bill status
passed
3 of 5 stages cleared
Introduction
Feb 2026
Committee Review
Apr 2026
House of Delegates Passage
Apr 2026
Senate Passage
Governor
Introduced Feb 13, 2026
Last action Apr 13, 2026
Maddy AI version diff · 1 comparison
What changed between versions
First - Clinical Research Pharmacies and Clinical Trials - Permits, Ownership, and Definition of Practice of Medicine
→
Third - Clinical Research Pharmacies and Clinical Trials - Permits and Ownership
·
3 edits
MINOR
The bill was amended to clarify that it prohibits individuals from being required to obtain a license to own a clinical research pharmacy. It also updated the list of sponsors to include several new delegates and added a committee report indicating the bill was favorably amended.
Scope change
The bill's scope was expanded to explicitly address licensing requirements for ownership, ensuring that owning a clinical research pharmacy does not trigger a requirement for a medical license.
ELIGIBILITY
Added language prohibiting the requirement of a medical license for individuals who own or have an ownership interest in a clinical research pharmacy.
TECHNICAL
Updated the list of bill sponsors to include additional delegates (Bagnall, Cullison, Guzzone, Hill, Hutchinson, S. Johnson, Kaufman, Kipke, Lopez, Martinez, Reilly, Rosenberg, Ross, Taveras, White Holland, and Woorman).
Added a committee report line stating the bill was adopted with a favorable report.
Floor votes · House of Delegates Mar 31, 2026
How they voted
130–5
Passed · 7 other
Total votes 142
Mar 31, 2026
D
Democratic103
96% Yea
R
Republican39
79% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
8
Key actions
4
Committee
4
Apr 13, 2026
Committee
Referred Rules
upper
Apr 13, 2026
Lower · Passed
Third Reading Passed
lower
Apr 13, 2026
Lower · Passed
Favorable with Amendments {
lower
Apr 11, 2026
Lower · Passed
Favorable with Amendments Report by Health
lower
Mar 31, 2026
House Of Delegates · Passed
House of Delegates Vote: pass (130-5-7)
house of delegates
Feb 13, 2026
Committee
First Reading Health
lower
16 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Aaron Kaufman
DDemocratic
P
Bonnie Cullison
DDemocratic
P
Deni Taveras
DDemocratic
P
Heather Bagnall Tudball
DDemocratic
P
Jared Solomon
DDemocratic
P
Jennifer White Holland
DDemocratic
P
Kim Ross
DDemocratic
P
Lesley Lopez
DDemocratic
P
Nic Kipke
RRepublican
P
Pam Guzzone
DDemocratic
P
Sandy Rosenberg
DDemocratic
P
Steve Johnson
DDemocratic
P
Teresa Reilly
RRepublican
P
Teresa Woorman
DDemocratic
P
Terri Hill
DDemocratic
P
Tom Hutchinson
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about HB 1426
Scope: MD
Hi! I can help you understand HB 1426. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline